Dublin, April 07, 2023 (GLOBE NEWSWIRE) -- The "HER2 Inhibitors Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
The global her2 inhibitors market is expected to grow from $6.61 billion in 2021 to $7.26 billion in 2022 at a compound annual growth rate (CAGR) of 9.9%. The HER2 inhibitors market is expected to reach $10.60 billion in 2026 at a CAGR of 9.9%.
North America was the largest region in the HER2 inhibitors market in 2022. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the HER2 inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The rise in the number of breast cancer cases across the globe is likely to contribute to the growth of the HER-2 inhibitors market during the forecast period. According to the American Cancer Society, as of January 2020, there were more than 3.5 million women with a history of breast cancer in the US.
This includes women currently being treated and women who have completed their treatment. According to the World Health Organization (WHO), breast cancer affected 2.3 million women globally in 2020, with 685 000 fatalities. Therefore, the rise in the breast cancer incidence rate globally is anticipated to boost the demand for the HER-2 inhibitors market over the forthcoming years.
High costs associated with the HER-2 inhibitors treatment are a major issue faced by citizens of many countries. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low average life expectancy.
Trastuzumab, a licensed HER2 inhibitor, has been the most expensive systemic cancer therapy procedure at a variety of disease sites. The cost of trastuzumab in India ranged from $774.6 to $841.35 per 440 mg vial. In patients with HER 2 positive early breast cancer, nearly 18 cycles of therapy based on trastuzumab are needed which further charges more than $1,335.52 in India. Therefore, the high cost of HER2 inhibitors is expected to hinder the growth of the HER2 inhibitors market.
Biotechnology companies are focusing on acquiring or partnering with biopharmaceutical companies to develop and promote the HER-2 inhibitors market. There have been several partnerships in recent years which help these companies to increase their HER-2 inhibitors portfolio, enhance their revenues and share the costs. For instance, in June 2020, Alphamab Oncology, a biotechnology company, collaborated with Sanofi, a pharmaceutical company, for investigating KN026 in combination with other drugs for the treatment of HER2 breast cancer. KN026 is a HER2 inhibitor developed by Alphamab Oncology.
In August 2021, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation acquired Trillium Therapeutics Inc for an undisclosed amount. This acquisition of Trillium will build a robust record of leadership in oncology, enhancing the hematology portfolio to enhance outcomes for people living with blood cancers worldwide. Trillium Therapeutics Inc is a Canada-based company that develops therapies for the treatment of cancer.
The countries covered in the HER2 inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Scope
Markets Covered
1) By Treatment: Monotherapy; Combination Therapy
2) By Application: Squamous Cell Carcinoma; Adenocarcinoma; Large Cell Carcinoma; Breast Cancer; Other Applications
3) By End User: Hospitals; Clinics; Other End Users
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2022 - 2026 |
| Estimated Market Value (USD) in 2022 | $7.26 billion |
| Forecasted Market Value (USD) by 2026 | $10.6 billion |
| Compound Annual Growth Rate | 9.9% |
| Regions Covered | Global |
Key Topics Covered:
1. Executive Summary
2. HER2 Inhibitors Market Characteristics
3. HER2 Inhibitors Market Trends And Strategies
4. HER2 Inhibitors Market - Macro Economic Scenario
5. HER2 Inhibitors Market Size And Growth
6. HER2 Inhibitors Market Segmentation
7. HER2 Inhibitors Market Regional And Country Analysis
A selection of companies mentioned in this report includes
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Puma Biotechnology Inc.
- Boehringer-Ingelheim
- Mylan
- Biocon
For more information about this report visit https://www.researchandmarkets.com/r/cyswuj
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
